Table 2.

Changes of questionnaire scores before and after treatment in two groups.

	Study (n = 33)			Control (n = 32)
	Before therapy	After therapy	P	Before therapy	After therapy	P
Compliance (%)	0.96 ± 0.10			0.97 ± 0.10		<0.001
Total VAS score	17.52 ± 1.42	8.30 ± 1.08	<0.001	17.00 ± 1.46	8.20 ± 1.06	<0.001
Total symptom relief score	20.15 ± 0.68	12.06 ± 0.70	<0.001	19.4 ± 0.75	11.84 ± 0.89	<0.001
Total RQLQ score	2.42 ± 0.17	1.29 ± 0.14	<0.001	2.52 ± 0.16	1.29 ± 0.16	<0.001
Activity limitation	2.62 ± 0.22	1.54 ± 0.19	<0.001	2.85 ± 0.20	1.59 ± 0.20	<0.001
Sleep problems	1.94 ± 0.22	0.83 ± 0.15	<0.001	1.84 ± 0.25	0.89 ± 0.17	0.004
Nonnose/eye symptoms	2.16 ± 0.20	0.95 ± 0.12	<0.001	2.09 ± 0.16	1.07 ± 0.14	<0.001
Practical problems	3.78 ± 0.24	1.90 ± 0.18	<0.001	3.69 ± 0.23	1.89 ± 0.21	<0.001
Nose symptoms	2.86 ± 0.22	1.80 ± 0.18	0.001	3.38 ± 0.22	1.68 ± 0.21	<0.001
Eye symptoms	1.61 ± 0.21	0.95 ± 0.15	0.022	1.82 ± 0.25	0.76 ± 0.16	0.001
Emotion	1.97 ± 0.22	1.04 ± 0.18	0.002	1.96 ± 0.25	1.14 ± 0.21	0.006
ESS score	6.54 ± 0.64	4.6 ± 0.61	0.026	5.66 ± 0.59	4.66 ± 0.61	0.254

Note: VAS: visual analogue scale; RQLQ: Rhinoconjunctivitis Quality of Life Questionnaire; ESS: Epworth sleepiness scale.